Back to Ovarian Cancer
This trial is complete. It is no longer accepting participants. Results may be available on ClinicalTrials.gov.

NCT00672295

NCT00672295
Completed Phase 1

Who may be able to join

Who might be able to join this trial:

  • You have been diagnosed with ovarian, peritoneal, or fallopian tube cancer, confirmed by a lab test of tissue or cells
  • Your cancer can be measured on a scan or other test
  • You are over 18 years old
  • Your doctor expects you to live for at least 3 more months
  • You are well enough to carry out daily activities to a reasonable degree (based on a standard performance scale — confirm with trial site)
  • Your bone marrow, kidneys, liver, and nerves are all working well enough (confirm with trial site)
  • You have not had chemotherapy, radiation, biological therapy, hormone therapy, or experimental treatments in the last 28 days
  • You have had no more than 3 previous chemotherapy treatments, which may have included carboplatin and paclitaxel
  • You are able to read and sign a consent form agreeing to take part
  • If you could become pregnant, you must have a negative pregnancy test before starting and use an effective form of birth control throughout the trial
  • A stored sample of your tumour tissue is available for testing, or you are willing to have a small biopsy taken within four weeks before joining; you must also agree to a second biopsy after the second round of treatment

Who may not be able to join:

  • Your ovarian tumour has been classified as "borderline" (low malignant potential)
  • You have had another type of cancer (other than certain common skin cancers) in the last 5 years
  • You have certain heart problems, including uncontrolled chest pain, a heart attack in the past 6 months, a specific heart rhythm condition called long QT syndrome, a history of serious irregular heartbeats, an abnormal heart rhythm reading on an ECG, or uncontrolled high blood pressure
  • You have a significant bleeding disorder (either inherited or diagnosed within the last year) that is not related to your cancer
  • You are currently taking certain medications known to affect heart rhythm — a detailed list should be confirmed with the trial site, but includes some antibiotics, antipsychotics, and heart medications among others
  • Your kidneys are not working well enough, based on a specific blood test result
  • You are taking blood thinners or medicines that affect how your blood clots
  • You have previously had radiation therapy covering more than 30% of your bone marrow
  • You have had a severe allergic reaction (grade 3) to paclitaxel or carboplatin in the past
  • You have a serious active infection, severe illness, active hepatitis, or another serious uncontrolled medical condition

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

Phase 1: approximately ~10% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.

Trial details

Status
Completed
Phase
Phase 1
Sponsor
AA Secord
Registry
clinicaltrials_gov
Start date
1 August 2007
Est. completion
1 September 2011

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

To determine maximal tolerated dose (MTD) of dasatinib in combination with paclitaxel and carboplatin during the first cycle of treatment

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 30 June 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

View original record on ClinicalTrials.gov